Abstract: Pelagic, surface floating, macroalga, Sargassum is harvested at large scale from a free-roaming farm floating freely on the ocean surface, monitored and tracked with GPS drifters and contained only by naturally occurring circular currents known as eddies or gyres, without aquaculture equipment. The farming technique occurs in open ocean through the utilization of system design and technology. Satellite imagery is interpreted to locate naturally occurring Sargassum aggregations or mats. Harvest vessel(s) travel to an identified mat, where only a portion of the natural mat is harvested as starter culture for a free-roaming farm. Cuttings are left behind to become new plants to restore the “mother mat” for no net loss of habitat and for migration for cohabitating organisms. The remainder of the biomass is transported to the identified free-roaming farm site which is in a suitable Eddie. GPS drifters are adhered with seedlings until the crop is ready for harvest.

Abstract: The invention pertains to a method for separating biomass from solid fermentation product wherein a slurry comprising biomass and solid fermentation product is provided to the top of a biomass separator unit and an aqueous medium is provided to the bottom of a biomass separator unit, while a product stream comprising solid fermentation product is withdrawn from the bottom of the biomass separator unit and a waste stream comprising biomass is withdrawn from the top of the biomass separator unit. It has been found that the method according to the invention makes it possible to provide a solid fermentation product which comprises very low amounts of remaining biomass, while product loss can be limited.

Abstract: The present invention describes a composition comprising a mixture of human foetal keratinocyte cells and human foetal fibroblast cells, the ratio between said keratinocyte and fibroblast cells ranging from 0.75 to 2.5, preferably being 1:1 or 7:3. This composition is advantageously included in a bandage, said bandage preferably being sterile and packaged in a container impermeable to microorganisms. The present invention finally concerns the use of this composition as a drug, in particular for treating a skin defect (wound, burn or ulcer).

Abstract: Described herein is a device and method for translocating a protein through a nanopore and monitoring electronic changes caused by different amino acids in the protein. The device comprises a nanopore in a membrane, an amplifier for providing a voltage between the cis side and trans side of the membrane, and an NTP driven unfoldase which processed the protein to be translocated. The exemplified unfoldase is the ClpX unfoldase from E. coli.

Abstract: Single dye fluorescent staining (with a membrane-associated dye such as FM 1-43 or FM 4-64) and the combination of differences in both intensity and spectral emission discriminate live from inactivated/dead bacteria and provides for rapid and accurate detection of live bacteria in mixed populations.

Abstract: Fertilized egg isolate, methods for preparing the fertilized egg isolate and uses thereof for treating mental health disorders and disease or conditions mediated by or associated with one or more glutamate receptors or by the neurokinin 2 (NK2) receptor.

Abstract: Methods for producing a fibrin matrix comprising a fusion peptide are described herein. In some embodiments, the method includes providing three different components, including a first component containing fibrinogen or a fibrinogen precursor and optionally, transglutaminase or a transglutaminase precursor, a second component containing thrombin or a thrombin precursor, and a third component containing a fusion peptide. In these embodiments, neither the first component nor the second component includes the fusion peptide. In some embodiments, the first or second components are premixed with the third component. The first, second and third components are mixed to form a fibrin matrix comprising a covalently linked fusion peptide. The mixing is carried out in a time frame of not more than 5 days. A kit for producing the fibrin matrix comprising a covalently linked fusion peptide is also described herein.

Abstract: Processes for transesterifying wax esters. Implementations may include: providing a feedstock including wax esters, contacting the feedstock with a lipase, and catalytically transesterifying the wax esters in the feedstock with the lipase to form a transesterified product. An oxidative stability index (OSI) of the transesterified product may be greater than an OSI of the feedstock.

Abstract: The present invention relates to a method for obtaining a high titer of enzyme mixture comprising cellulases, hemicellulases and ?-glucosidases in reutilization of waste water generated during hot water extraction of lignocellulosic biomass or biorefinery waste water using Penicillium funiculosum MRJ-16 mutant strain. The cellulose or lignocellulosic biomass used in the fermentation process is selected from the group consisting of rice straw, wheat straw, corn stover, cotton stalk or a combination thereof. The enzyme mixture obtained by the present process is used for the saccharification of acid pretreated lignocellulosic biomass.

Abstract: The subject matter of the instant invention relates to methods of enhancing harvesting of phages against a targeted host bacteria, as well as methods of identifying phages likely to have an enhanced propensity to infect and kill an infectious pathogenic bacteria in vivo, from samples comprising phages. The invention also relates to phage libraries, pharmaceutical compositions, methods of treatment, and phage-based diagnostic methods and methods of detecting bacteria related thereto.

Abstract: The present invention relates to embedding live or dead microorganisms and/or bioactive materials in a protective dry formulation matrix, wherein the formation includes the bioactive microorganism or material, a formulation stabilizer agent, and a protective agent. The formulation agent is prepared by dispersing all the solid components in a solution, with or without a vacuum, and cooling the solution to a temperature above its freezing temperature. The methods include a primary drying step of the formulation at a desired temperature and time period, and an accelerated secondary drying step under maximum vacuum and elevated temperature, to achieve a final desirable water activity of the dry material.

Abstract: This document provides methods and materials for treating a mammal (e.g., a human) having one or more stenotic blood vessels. For example, amnion coated balloons that can be used in balloon angioplasty are provided.

Abstract: The present invention relates to a pharmaceutical composition for inhibiting rejection of transplanted cells including a high mobility group box 1 A domain (HMGB1A) as an active ingredient. The use of the pharmaceutical composition can minimize immunological rejection, which may occur upon cell transplantation, and increase the success rate of cell transplantation.

Abstract: Drug targets, pathways, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed.

Abstract: Among the various aspects of the present disclosure is the provision of a method of detection, treatment, and monitoring of cardiovascular disease or a foot wound by detection of a novel biomarker, Fatty Acid Synthase (FAS). Briefly, therefore, the present disclosure is directed to methods that allow for improved, noninvasive, and reliable diagnosis of these conditions, particularly in subjects suffering from Type 2 Diabetes (T2D).

Abstract: The invention relates to a mass spectrometric method to determine microbial resistances to antibiotics. The decrease or modification of specific nutrient components by microbes, and thus the metabolism of the microbes, is determined mass spectrometrically in culture media containing antibiotics. Hence it is not the microbes which are introduced into the mass spectrometric analysis, but the culture medium. The special nutrient components which are subject to the mass spectrometric observation are indicators for the metabolism exhibited by the microbes in the culture in the presence of antibiotics, and are thus indicators for their susceptibility or resistance.

Abstract: Provided are a functional food or pharmaceutical composition or a method for preventing, alleviating or treating hyperphosphatemia and chronic kidney disease and treating chronic kidney disease using the composition comprising Lactobacillus sp. KCCM 11826P having excellent phosphorus-absorbing ability.

Abstract: The invention provides compositions comprising bacterial strains for treating and preventing a neurodegenerative disorder.

Abstract: In one aspect, the present invention provides methods for preparing a fermentation product. The methods include pre-treating a mixture of biomass and ionic liquid, wherein the ionic liquid comprises a choline cation and the biomass comprises polysaccharide and lignin. The methods further include forming hydrolysates from the introduction of glycoside hydrolase to the pre-treated mixture at conditions sufficient to produce a sugar composition mixture for fermentation steps. The present invention provides methods for loading biomass mixtures in a batch-fed process, wherein the biomass slurries can be loaded into water or a concentrated sugar composition for hydrolysate production. The methods can be performed in a one-pot process, wherein the ionic liquids are present in the mixtures throughout each step. Aspects of the invention provide compositions of sugar composition mixtures and fermentation product mixtures.

Abstract: The present invention relates to a yeast strain likely to be obtained by hybridizing a strain S1 with a strain S2, said yeast strain presenting, according to test A, the following characteristics: fermentation kinetics from 15 to 22 days at a temperature of 24° C.; and resistance with an alcoholic strength of more than or equal to 15% v/v; and a nitrogen requirement of less than or equal to 200 ppm, to the method of producing this strain and to its use.